Uvax Bio Announces Publication of Results from Preclinical Studies of HIV Vaccine Candidates Uvax Bio-owned vaccines demonstrated significant improvement in immune response compared with current vaccine strategiesPhase 1 clinical trial sponsored by National Institutes of Health expected to...

POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19 BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...

POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19 BUFFALO, N.Y., Feb. 06, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a...

Celsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform Results Indicate Induction of Adaptive Immune Response Against SARS-CoV-2 Company Plans Additional Development Work to Further Optimize its Vaccine Platform Through Vector Compositions, Delivery...